KEI and UACT comments on the prospective grant of exclusive licenses to Sinotau and MTTI

On August 27, 2018, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) filed comments to the NIH regarding the prospective grant of two separate exclusive licenses to Sinotau Pharmaceutical Group and Molecular Targeting Technologies, Inc. (MTTI),… Continue Reading

Sanctions for Non Disclosure, as Set Out in Article 6 of the WIPO Basic Proposal on Intellectual Property, Genetic Resources and Traditional Knowledge, Should Include Possible Revocation of a Patent

On May 15, 2024, Knowledge Ecology International published an article on “Sanctions for Non Disclosure, as Set Out in Article 6 of the WIPO Basic Proposal on Intellectual Property, Genetic Resources and Traditional Knowledge, Should Include Possible Revocation of a… Continue Reading

UN rejects amendment to limit technology transfer to “voluntary and mutually agreed terms” in resolution on global health

Revised May 6, 2024 Against the backdrop of the tortuous negotiations among WHO Member States on technology transfer and know-how at the last mile of the pandemic agreement talks, on Wednesday, 1 May 2024, Switzerland offered a surprise amendment in… Continue Reading

The Article 13 Express: WHA 77.1 – WHO Pandemic Agreement

On Wednesday, 17 April 2024 at 15:25 CEST, the WHO secretariat circulated an advance, unedited English version of the proposed draft WHO Pandemic Agreement; the WHO secretariat also circulated the accompanying draft resolution, WHA77.1 WHO Pandemic Agreement. For KEI’s analysis… Continue Reading

Request for CMS to provide a Bayh-Dole Section 202 license and a 28 USC 1498 authorization and consent to use three patents listed in the FDA Orange Book for the cancer drug enzalutamide

Letter from KEI, UACT and UAEM to Chiquita White Brooks-Lasure, Administrator of the Office of the Administrator, Centers for Medicare and Medicaid Services, at HHS, asking that CMS to provide a Bayh-Dole Section 202 license and a 28 USC 1498… Continue Reading

KEI Comments to the NIH on Exclusive License to UK Firm Poolbeg Pharma

On April 8, 2024, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the prospective grant of an exclusive license to Poolbeg Pharma Limited, a UK-based company. The license concerns, “Adoptive T Cell Therapy Products… Continue Reading

INB 9 – Oral statement by Knowledge Ecology International

On Monday, 18 March 2024, Knowledge Ecology International (KEI) delivered the following oral statement (in person) at the 9th meeting of the World Health Organization’s (WHO) Intergovernmental Negotiating Body (INB). With respect to Article 11.2, the current references to “to… Continue Reading

Request for Amendment to add Risdiplam for Spinal Muscular Atrophy (SMA) to Schedule 1 of the Canadian Patent Act

On March 1st, Knowledge Ecology International sent a letter to The Hon. Mark Holland, Ministry of Health, and The Hon. François-Philippe Champagne, Minister of Innovation, Science, and Industry, urging the prompt consideration of adding risdiplam, a drug to treat spinal… Continue Reading